Icosavax, Announces Agreement to be Acquired by AstraZeneca
– Icosavax stockholders to receive $15.00 per share in cash at closing plus non-tradeable contingent value right (CVR) of up to $5.00 per share – – Representing a total equity value of up to $1.1 billion including the CVRÂ – Icosavax, announced it has entered into a definitive agreement pursuant to......